Associated Genetic Biomarkers
ESR2 is altered in 1.30% of all cancers with conventional glioblastoma multiforme, glioblastoma, melanoma, skin squamous cell carcinoma, and adenocarcinoma of unknown primary having the greatest prevalence of alterations .
The most common alterations in ESR2 are ESR2 Mutation (1.18%), ESR2 V370I (0.18%), ESR2 A252T (0.09%), ESR2 A252V (0.07%), and ESR2 A275T (0.07%) .
ESR2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains ESR2 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with ESR2 status in the inclusion eligibility criteria most commonly target breast carcinoma .
The most frequent alterations to serve as inclusion eligibility criteria are ESR2 Expression and ESR2 Overexpression .
Estradiol is the most frequent therapy in trials with ESR2 as an inclusion criteria .
Significance of ESR2 in Diseases
Breast Carcinoma +
ESR2 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ESR2 status and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.